Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option?
- Resource Type
- Abstract
- Source
- In
Gynecologic Oncology October 2020 159 Supplement 1:21-22 - Subject
- Language
- ISSN
- 0090-8258